Compass Therapeutics宣布Tovecimig数据获选于2026年ESMO大会进行口头报告

美股速递
Jul 17

Compass Therapeutics, Inc. (CMPX) 宣布,其候选药物Tovecimig的相关研究数据已被接收,并获选在2026年欧洲肿瘤内科学会(ESMO)大会上以口头报告形式进行展示。这一进展标志着公司在该候选药物的临床开发上取得了重要阶段性成果,并获得了国际顶级学术会议的认可。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10